Decision on Medicines Containing Phenylephrine for Use as Decongestants

Gerald Giam inquired about the Health Sciences Authority's (HSA) plans to cease approving phenylephrine-based medicines as decongestants following a US FDA advisory panel's vote, including timelines and reasons for any inaction.
Ong Ye Kung responded that phenylephrine has a long history of safe use in Singapore and globally, and HSA is reviewing its effectiveness relevance locally.
Ong Ye Kung noted that the US FDA has not yet made a final decision despite the advisory panel's recommendation, and HSA will update the public if regulatory action is taken.

Gerald Giam inquired about the Health Sciences Authority's (HSA) plans to cease approving phenylephrine-based medicines as decongestants following a US FDA advisory panel's vote, including timelines and reasons for any inaction.
Ong Ye Kung responded that phenylephrine has a long history of safe use in Singapore and globally, and HSA is reviewing its effectiveness relevance locally.
Ong Ye Kung noted that the US FDA has not yet made a final decision despite the advisory panel's recommendation, and HSA will update the public if regulatory action is taken.

Gerald Giam inquired about the Health Sciences Authority's (HSA) plans to cease approving phenylephrine-based medicines as decongestants following a US FDA advisory panel's vote, including timelines and reasons for any inaction.
Ong Ye Kung responded that phenylephrine has a long history of safe use in Singapore and globally, and HSA is reviewing its effectiveness relevance locally.
Ong Ye Kung noted that the US FDA has not yet made a final decision despite the advisory panel's recommendation, and HSA will update the public if regulatory action is taken.

Gerald Giam inquired about the Health Sciences Authority's (HSA) plans to cease approving phenylephrine-based medicines as decongestants following a US FDA advisory panel's vote, including timelines and reasons for any inaction.
Ong Ye Kung responded that phenylephrine has a long history of safe use in Singapore and globally, and HSA is reviewing its effectiveness relevance locally.
Ong Ye Kung noted that the US FDA has not yet made a final decision despite the advisory panel's recommendation, and HSA will update the public if regulatory action is taken.

Summary